Your Article Summary
See Latest ArticlesOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
Expert Opinion in Pharmacotherapy, 06/30/09
Volavka J et al. - The classification of antipsychotics into the two groups is no longer useful. The treatment selection for an individual patient should focus on the suitability of an individual antipsychotic for that patient rather than on the group membership of the drug.
Related Articles
Auditory gating deficit to human voices in schizophrenia: A MEG study
Schizophrenia Research, 10/01/09
Relevance Score: 93%
Age at onset and cognition in schizophrenia: meta-analysis
British Journal of Psychiatry, 10/06/09
Relevance Score: 92%
Beyond symptom dimensions: Schizophrenia risk factors for patient groups derived by latent class analysis
Schizophrenia Research, 10/30/09
Relevance Score: 91%
Functional Magnetic Resonance Imaging of Inner Speech in Schizophrenia
Biological Psychiatry, 10/26/09
Relevance Score: 91%
Sensory Processing in Schizophrenia: Neither Simple nor Intact
Schizophrenia Bulletin, 10/19/09
Relevance Score: 91%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/04/09
Combination therapy of 17(beta)-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain
Molecular Pharmacology, 12/04/09